Are Dell’s shareholders on Xanax?

Are Dell’s shareholders on Xanax? The company has finally bowed out of its mad bidding war for 3PAR. Yet its investors displayed neither much concern about overpayment nor relief about the deal being dropped. After a decade of scandals, missed opportunities and dismal performance, they may have stopped caring.
They had reason to worry. Dell appeared […]

Deals wrap: Factoring in China

Chinese and other investors have approached at least one big Canadian pension manager about a bid for Canada’s Potash Corp to rival BHP Billiton’s hostile offer. This is one of the first pieces of hard evidence to back up speculation that China is looking for a way to derail a takeover of Potash Corp by […]

Live Video: Bernanke and Bair testify before the FCIC

Live video of Thursday’s Financial Crisis Inquiry Commission testimony from Fed Chairman Ben Bernanke and Federal Deposit Insurance Corp Chairman Sheila Bair.

Sphere: Related Content

Deals wrap: Whopper deal sealed

Burger King agreed to be bought by investment firm 3G Capital for $3.26 billion. The deal represents a 46 percent premium to Burger King’s share price before news of the deal talks emerged on Wednesday. *View article *View WSJ article on how tasty a Burger King deal is
Hewlett-Packard raised its offer by $3 to $33 […]

Reheating Burger King won’t be another LBO whopper

It’s easy to see why private equity firms might salivate at the prospect of another bite at Burger King. The fast-food chain has made a fortune for a trio of buyout barons who acquired the company in 2002 and flipped it onto public markets four years later. But Burger King won’t be another LBO whopper.
Back […]

Deals wrap: Mulling a Whopper of a deal

Burger King,which has underperformed rivals and has forecast weak demand, is considering a sale, a source familiar with the situation said. One potentially interested party is 3i Group, a source told Reuters.  *View article
August’s unseasonable burst of dealmaking — the busiest in over a decade — could herald a wider rebound in M&A for […]

Sanofi, Genzyme play chicken over price

“Let me in and I might go higher.” That in a nutshell is the message Sanofi-Aventis chief executive Chris Viehbacher is sending Genzyme’s management in making public his $18.5 billion offer to buy the U.S. biotech company. The all-cash structure is intended to show that the French pharmaceuticals group is serious. But the lowball $69-a-share […]

HP tries big buyback to quell investor discontent

Sometimes an ounce of prevention is worth a pound of cure. Case in point: Hewlett-Packard. Like many tech concerns, it is sitting on a large cash pile. But the company’s bidding war with Dell for control of 3PAR raises fears it may squander its $15 billion hoard on overpriced baubles. Promising to repurchase $10 billion […]

Next Page »